MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.31

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.27

Max

1.31

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+103.82% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.4M 73M
Vorheriger Eröffnungskurs	1.31
Vorheriger Schlusskurs	1.31

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Apr. 2026, 17:26 UTC

Wichtige Nachrichtenereignisse

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. Apr. 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Market Talk Roundup: Latest on U.S. Politics

7. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. Apr. 2026, 23:44 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Apr. 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:37 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. Apr. 2026, 23:15 UTC

Market Talk

Wichtige Nachrichtenereignisse

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. Apr. 2026, 23:04 UTC

Wichtige Nachrichtenereignisse

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. Apr. 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Apr. 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. Apr. 2026, 23:01 UTC

Wichtige Nachrichtenereignisse

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. Apr. 2026, 22:58 UTC

Wichtige Nachrichtenereignisse

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. Apr. 2026, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

7. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Apr. 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. Apr. 2026, 19:17 UTC

Wichtige Nachrichtenereignisse

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. Apr. 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. Apr. 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. Apr. 2026, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. Apr. 2026, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. Apr. 2026, 18:39 UTC

Akquisitionen, Fusionen, Übernahmen

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. Apr. 2026, 18:24 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. Apr. 2026, 16:21 UTC

Wichtige Nachrichtenereignisse

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. Apr. 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

103.82% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 103.82%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.